• About us
• Contact

Advertisement

Organisation › Details

Nycomed International Management GmbH

Nycomed is a privately owned global pharmaceutical company with a differentiated portfolio focused on branded medicines in gastroenterology, respiratory and inflammatory diseases, pain, osteoporosis and tissue management. An extensive range of OTC products completes the portfolio. Its R&D is structured around partnerships and in-licensing is a cornerstone of the company's growth strategy. Nycomed employs 12,000 associates worldwide, and its products are available in more than 100 countries. It has strong platforms in Europe and in fast-growing markets such as Russia/CIS and Latin America. While the US and Japan are commercialised through best-in-class partners, Nycomed plans to further strengthen its own position in key Asian markets. Headquartered in Zurich, Switzerland, the company generated total sales of €3.2 billion in 2009 and an adjusted EBITDA of €1.1 billion *

 

	Start	2007-12-10 existent
	Group	Takeda (Group)
	Industry	pharmaceutical
	Region	Zürich ZH
	Country	Switzerland
	Street	130 Thurgauerstr.
	City	8152 Glattpark-Opfikon (Zurich)
	Tel	+41-44-555-1000
		Address record changed: 2020-12-02
Basic data	Employees	H: 10,001 to 50,00 (2010-04-27)
	Currency	EUR
	Annual sales	3,200,000,000 (sales (2009) 2009-12-31)
		* Document for »About Section«:
		Record changed: 2023-07-10

Advertisement

More documents for Takeda (Group)

• [1] T-Curx GmbH. (8/28/23). "Press Release: T-Curx GmbH Announces Appointment of Two Industry Leaders to Its Board of Directors"....
• [2] Fresenius Medical Care AG & Co. KGaA. (12/5/22). "Press Release: Helen Giza to Take Over as Chief Executive Officer of Fresenius Medical Care"....
• [3] Heidelberg Pharma AG. (9/9/22). "Press Release: Heidelberg Pharma Announces Conclusion of License Agreement with Partner Takeda To Develop an Antibody Targeted Amanitin Conjugate". Ladenburg....
• [4] Evotec SE. (3/22/21). "Press Release: Evotec and Takeda Enter Strategic RNA Targeting Drug Discovery and Development Alliance". Hamburg....
• [5] Evotec SE. (4/6/20). "Press Release: Evotec and Takeda Enter into Multi-year Gene Therapy Research Alliance". Hamburg....
• [6] Evotec SE. (3/26/20). "Press Release: Evotec SE Fiscal Year 2019 Results". Hamburg....
• [7] Evotec SE. (9/24/19). "Press Release: Evotec and Takeda Enter Collaboration Agreement to Discover Clinical Candidates across Multiple Therapeutic Areas". Hamburg....
• [8] Adrenomed AG. (8/29/19). "Press Release: Adrenomed Supervisory Board Appoints Jens Schneider-Mergener as CEO and Jens Zimmermann, CMO, Joins the Executive Board". Hennigsdorf....
• [9] Centogene AG. (5/9/19). "Press Release: Centogene Expands Executive Leadership Team". Cambridge, MA & Rostock....
• [10] Centogene AG. (4/2/19). "Press Release: Centogene Announces the Appointment of Dr. Flemming Ornskov to the Supervisory Board as Non-Executive Chairman". Rostock & Berlin....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Advertisement

» top

» Imprint  |  » Data Privacy  |  » Contact  |  The use of this website requires to accept the » Disclaimer!   |  A project of [iito] Business Intelligence © 2002-2024. Made in Germany.